重组人FGF21改善2型糖尿病小鼠局灶性脑缺血后神经功能结局
该研究在2型糖尿病db/db小鼠及非糖尿病db/+对照小鼠中建立永久性大脑中动脉远端闭塞模型,于卒中后6小时开始每日给予rFGF21治疗14天。结果显示rFGF21可改善全身代谢紊乱、恢复PPARγ活性、抑制促炎反应,并减轻白质完整性丧失、脑梗死体积及神经功能缺损。
要点
- rFGF21于卒中后6小时启动、每日治疗14天,可改善糖尿病小鼠卒中后神经功能结局。
- rFGF21显著减轻糖尿病小鼠卒中后白质完整性丧失与脑梗死体积。
- 机制可能涉及全身代谢调节及PPARγ激活相关的脑内抗促炎作用。
核心结论
- rFGF21可能是治疗2型糖尿病合并缺血性卒中的新型疾病修饰策略候选药物。
研究设计与样本
- 研究采用2型糖尿病db/db小鼠与非糖尿病遗传对照db/+小鼠,建立永久性大脑中动脉远端闭塞模型。
- 卒中后6小时开始每日给予rFGF21,持续14天,评估全身代谢、PPARγ活性、炎症因子mRNA表达、小胶质细胞/巨噬细胞活化、神经功能缺损、脑梗死及白质完整性。
主要发现
- 糖尿病db/db小鼠在永久性局灶缺血后表现为代谢紊乱、更严重的脑损伤和神经功能损害,尤其促炎反应及白质完整性丧失加重。
- 每日rFGF21治疗14天显著使全身代谢紊乱正常化,恢复PPARγ活性下降,抑制促炎细胞因子mRNA表达及M1样小胶质细胞/巨噬细胞活化。
- rFGF21显著减少卒中后14天内的白质完整性丧失、缺血性脑梗死及神经功能缺损。
临床怎么用
- 提示对2型糖尿病合并缺血性卒中患者,rFGF21可能作为改善神经功能结局的潜在靶向治疗方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- The complexity and heterogeneity of stroke, as well as the associated comorbidities, may render neuroprotective drugs less efficacious in clinical practice. Therefore, the development of targeted therapies to specific patient subsets has become a high priority in translational stroke research. Ischemic stroke with type 2 diabetes mellitus has a nearly double mortality rate and worse neurological outcomes. In the present study, we tested our hypothesis that rFGF21 (recombinant human fibroblast growth factor 21) administration is beneficial for improving neurological outcomes of ischemic stroke with type 2 diabetes mellitus. Methods- Type 2 diabetes mellitus db/db and nondiabetic genetic control db/+ mice were subjected into permanent focal ischemia of distal middle cerebral artery occlusion, we examined the effects of poststroke administration with rFGF21 in systemic metabolic disorders, inflammatory gatekeeper PPARγ (peroxisome proliferator-activated receptor γ) activity at 3 days, mRNA expression of inflammatory cytokines and microglia/macrophage activation at 7 days in the perilesion cortex, and last neurological function deficits, ischemic brain infarction, and white matter integrity up to 14 days after stroke of db/db mice. Results- After permanent focal ischemia, diabetic db/db mice presented confounding pathological features, including metabolic dysregulation, more severe brain damage, and neurological impairment, especially aggravated proinflammatory response and white matter integrity loss. However, daily rFGF21 treatment initiated at 6 hours after stroke for 14 days significantly normalized systemic metabolic disorders, rescued PPARγ activity decline, inhibited proinflammatory cytokine mRNA expression, and M1-like microglia/macrophage activation in the brain. Importantly, rFGF21 also significantly reduced white matter integrity loss, ischemic brain infarction, and neurological function deficits up to 14 days after stroke. The potential mechanisms of rFGF21 may in part consist of potent systematic metabolic regulation and PPARγ-activation promotion-associated antiproinflammatory roles in the brain. Conclusions- Taken together, these results suggest rFGF21 might be a novel and potent candidate of the disease-modifying strategy for treating ischemic stroke with type 2 diabetes mellitus.
引用
- Jiang Y, Liu N, Wang Q, et al. Endocrine Regulator rFGF21 (Recombinant Human Fibroblast Growth Factor 21) Improves Neurological Outcomes Following Focal Ischemic Stroke of Type 2 Diabetes Mellitus Male Mice. Stroke. 2018. PMID: 30571410. doi:10.1161/STROKEAHA.118.022119
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。